Cargando…
Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine
Fremanezumab is a fully humanized monoclonal antibody (IgG2Δa) that targets calcitonin gene-related peptide (CGRP), a key neuropeptide involved in the pathophysiology of migraine. Fremanezumab is approved for quarterly and monthly subcutaneous dosing for the preventive treatment of migraine in adult...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Portland Press Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487173/ https://www.ncbi.nlm.nih.gov/pubmed/32832978 http://dx.doi.org/10.1042/ETLS20200018 |